Fladrafinil
Bis-fluorinated Adrafinil analog, aggression-reducing profile, investigational.
Pharmacology
Contents
Related comparisons
Adrafinil vs FladrafinilWHAT IS FLADRAFINIL?
Detailed overview
Fladrafinil (CRL-40,941) is a bis-fluorinated derivative of Adrafinil, originally developed by Lafon (France) (PMID 27928893). Its eugeroic activity is similar to Adrafinil`s but 3-4× more potent with a 12-16 h duration. Mechanism: hepatic conversion to a Modafinil-like active metabolite → DAT inhibition + orexin/histamine modulation. Animal models also describe a pronounced aggression reduction (US Patent 4489095). The fluorine substitution slows hepatic metabolism → longer effect but elevated hepatotoxicity risk with chronic dosing (LFT monitoring). Banned in the UK under the Psychoactive Substances Act (since 2016). No human clinical trials; not approved anywhere.
Mechanism
Modafinil-prodrug profile
Half-life
No validated human data
Legal status
Not approved anywhere
Receptor profile
- Dopamine transporter (DAT)Moderate
- Orexin (hypothalamic wake system)Moderate
- Histamine (tuberomammillary system)Moderate
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Insomnia and disrupted sleep, especially with late dosing due to the 12-16 hour duration
- Headache, a typical side effect of modafinil-class eugeroics
- Anxiety, irritability and overstimulation, more pronounced at higher doses
- Reduced appetite and dry mouth
- Palpitations, raised blood pressure and heart rate from the dopaminergic-stimulant effect
- Elevated liver enzymes and risk of hepatotoxicity with chronic use (as seen with adrafinil)
- Tolerance development with repeated use
Contraindications · 6
- No human clinical safety data, long-term effects unknown, not approved anywhere
- Existing liver impairment, avoid with other hepatotoxic agents or alcohol (liver function monitoring warranted)
- Cardiovascular disease, hypertension or arrhythmia due to the blood-pressure and heart-rate raising effect
- Pregnancy and breastfeeding, safety not established
- Anxiety disorders, avoid combining with other stimulants due to overstimulation
- Its modafinil-like metabolite may reduce the efficacy of hormonal contraceptives (CYP3A4 induction)
Related Nootropics
Same therapeutic category
FAQ
FAQ
Fladrafinil is a modified, fluorinated version of the well-known wakefulness-promoting compound adrafinil, designed to be stronger and longer-lasting than the original. Per the description it produces a similar wakefulness-boosting effect to adrafinil, just more potent and longer-acting, and is also credited with an aggression-reducing profile. This is an experimental, poorly researched compound rather than an established, widely used substance.
Telegram
Have a question about Fladrafinil?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.